Breaking News, Financial News

Kupando Secures €10M More in Series A Funding for Oncology, Infectious Disease Programs

This latest round brings the company’s total Series A financing to €23 million.

Author Image

By: Patrick Lavery

Content Marketing Editor

Kupando is getting an additional €10 million (US$11.5 million) Series A financing to target tumors in oncology, and infectious diseases. Altogether, this latest round brings the company’s total Series A funding to €23 million (US$26.47 million). A Mission in Oncology and Infectious Diseases Kupando is a biopharmaceutical company developing a toll-like receptor (TLR) 4/7 agonist stimulating innate immunity and inducing trained immunity. A Phase Ib clinical study of Kupando’s lead candida...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters